Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer

Lung Cancer

Volumn 67, Issue 3, 2010, Pages 361-365

  Suzuki, Yuzo ^a   Suda, Takafumi ^a   Furuhashi, Kazuki ^a   Suzuki, Masako ^a   Fujie, Michio ^a   Hahimoto, Dai ^a   Nakamura, Yutaro ^a   Inui, Naoki ^a   Nakamura, Hirotoshi ^a   Chida, Kingo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Indoleamine 2,3 dioxygenase; Kynurenine; Lung cancer; Tryptophan

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; TRYPTOPHAN;

ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE COURSE; EARLY CANCER; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TANDEM MASS SPECTROMETRY;

AGED; DISEASE PROGRESSION; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TRYPTOPHAN;

EID: 75749113671     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.05.001     Document Type: Article

References (23)

1. Zou W. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 5 (2005) 263-274
2. Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 6 (2006) 295-307
3. Munn D.H., and Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117 (2007) 1147-1154
4. Mellor A.L., and Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4 (2004) 762-774
5. Stone T.W., and Darkington L.G. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1 (2002) 609-620
6. Uyttenhove C., Pilotte L., Théate I., Stroobant V., Colau D., Parmentier N., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9 (2003) 1269-1274
7. Ino K., Yoshida N., Kajiyama H., Shibata K., Yamamoto E., Kidokoro K., et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 95 (2006) 1555-1561
8. Brandacher G., Perathoner A., Ladurner R., Schneeberger S., Obrist P., Winkler C., et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12 (2006) 1144-1151
9. Okamoto A., Nikaido T., Ochiai K., Takakura S., Saito M., Aoki Y., et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 11 (2005) 6030-6039
10. Mellor A.L., Keskin D.B., Johnson T., Stroobant V., Colau D., Parmentier N., et al. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 168 (2002) 3771-3776
11. Weinlich G., Murr C., Richardsen L., Winkler C., and Fuchs D. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 214 (2007) 8-14
12. Schroecksnadel K., Winkler C., Fuith L.C., and Fuchs D. Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett 223 (2005) 323-329
13. Pawlak K., Domaniewski T., Mysliwiec M., and Pawlak D. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 204 (2009) 309-314
14. Sobin L., and Wittekind C. UICC TNM classification of malignant tumors. 6th ed. (2002), Wiley-Liss, New York
15. Travis W.D., Colby T.V., and Corrin B. Histological typing of lung and pleural tumours. 3rd ed. (1999), Springer-Verlag, Berlin
16. Yamada K., Miyazaki T., Shibata T., Hara N., and Tsuchiya M. Simultaneous measurement of tryptophan and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B: Anal Technol Biomed Life Sci 867 (2008) 57-61
17. Amirkhani A., Heldin E., Markides K.E., and Bergquist J. Quantitation of tryptophan, kynurenine and kynurenic acid in human plasma by capillary liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr B: Anal Technol Biomed Life Sci 780 (2002) 381-387
18. Amirkhani A., Rajda C., Arvidsson B., Bencsik K., Boda K., Seres E., et al. Interferon-beta affects the tryptophan metabolism in multiple sclerosis patients. Eur J Neurol 12 (2005) 625-631
19. Huang A., Fuchs D., Widner B., Glover C., Henderson D.C., and Allen-Mersh T.G. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 86 (2002) 1691-1696
20. Karanikas V., Zamanakou M., Kerenidi T., Dahabreh J., Hevas A., Nakou M., et al. Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther 6 (2007) 1258-1262
21. Schroecksnadel K., Fiegl M., Prassl K., Winkler C., Denz H.A., and Fuchs D. Diminished quality of life in patients with cancer correlates with tryptophan degradation. J Cancer Res Clin Oncol 133 (2007) 477-485
22. Weiss G., Schroecksnadel K., Mattle V., Winkler C., Konwalinka G., and Fuchs D. Possible role of cytokine-induced tryptophan degradation in anemia of inflammation. Eur J Haematol 72 (2004) 130-134
23. Denz H., Orth B., Weiss G., Hermann R., Huber P., Wachter H., et al. Weight loss in patients with hematological neoplasias is associated with immune system stimulation. Clin Invest 71 (1993) 37-41